# Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1)

> **NCT03676010** · — · ACTIVE_NOT_RECRUITING · sponsor: **Institut Bergonié** · enrollment: 265 (actual)

## Conditions studied

- Cancer

## Interventions

- **OTHER:** Sarcoma and GIST
- **OTHER:** Breast cancer
- **OTHER:** Pancreatic cancer
- **OTHER:** Renal cell carcinoma
- **OTHER:** Colon cancer
- **OTHER:** Solid tumours undergoing image-guided tumor ablation
- **OTHER:** (early) Non Small Cell Lung Cancer

## Key facts

- **NCT ID:** NCT03676010
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-09
- **Primary completion:** 2015-01
- **Final completion:** 2026-12
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676010, "Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03676010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*